In recent years, with the transformation of human health concepts and medical models, the unique advantages of traditional Chinese medicine have gradually been recognized and accepted
by more and more countries and regions.
In this context, the pace of Chinese traditional Chinese medicine enterprises to the international market has also begun to accelerate
.
It is understood that in order to further promote the development and internationalization of the traditional Chinese medicine industry, the state has successively issued a series of favorable policies, including the "Opinions on Promoting the Innovative Development of Traditional Chinese Medicine", "The Implementation Opinions on Promoting the Innovative Development of Foreign Trade", "The Notice on Several Measures to Support the High-quality Development of the National Traditional Chinese Medicine Service Export Base", and under the impetus of these policies, Chinese medicine has begun to achieve positive results
in the world.
According to reports, as of now, China has built 31 national TCM service export bases, and the total export trade of TCM products during the "13th Five-Year Plan" period has reached 28.
19 billion US dollars; the State Administration of Traditional Chinese Medicine has supported domestic TCM institutions to build 30 high-quality TCM overseas centers in the "Belt and Road" countries, and 56 TCM international cooperation bases in China, providing high-quality TCM services
for the people of the "Belt and Road" countries.
Overall, the policy on the internationalization of Chinese medicine has been continuously improved, the environment has been continuously optimized, and the support has been continuously increased, so that the pace of Chinese medicine going out has been accelerated
.
At the same time, many Chinese medicine companies have also begun to usher in more overseas benefits by taking advantage of
Dongfeng.
For example, during the 14th Five-Year Plan period, "Chinese medicine going to sea" was an important direction of Tongrentang traditional Chinese medicine, and the main variety was Angong Niuhuang Pill
.
Among them, the sales of Angong Niuhuang Pill in Southeast Asia are very strong
.
Zhiyan Consulting once released a research report saying that according to Chinese customs data, the number of Chinese Angong cattle yellow pills exported in 2020 was 14161 kg, an increase of 38.
4% year-on-year; The export value was 29.
383 million US dollars, an increase of 17.
6% year-on-year, of which the region with the largest number of exports was Vietnam, followed by Hong Kong and Indonesia
.
Tongrentang said, "The company is currently preparing for the local registration and production of Angong Niuhuang Pill in Southeast Asia, and it is expected that the proportion of revenue in the Southeast Asian market will increase
significantly in the future.
" ”
It is worth noting that the National Health Commission recently held a press conference
on the progress and effectiveness of international cooperation and exchanges on health since the 18th National Congress of the Communist Party of China.
At the meeting, the relevant person in charge said that in the future, it is also necessary to combine the local common diseases in the recipient countries to formulate a traditional Chinese medicine diagnosis and treatment plan for advantageous diseases, better play the characteristic advantages of traditional Chinese medicine, improve popularity, and support the construction of "traditional Chinese medicine centers" to create a foreign aid brand
with Chinese characteristics.
It is also necessary to support Chinese enterprises to actively carry out overseas registration and sales of Chinese medicines, joint research, promote localized production, and make Chinese medicines in China better serve
the people of recipient countries.
In this regard, the industry believes that the overseas export of traditional Chinese medicine will be accelerated
again.
In this context, the export of Chinese herbal medicines and Traditional Chinese medicine products in China will continue to grow and open up more new markets
.
For traditional Chinese medicine enterprises, it will usher in more opportunities
for inheritance and development.
However, it should be noted that at the same time, in the future, the innovation of proprietary Chinese medicines and the overseas of proprietary Chinese medicines will also become the key research areas of enterprises
.
